07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

Almitrine-containing medicines regulatory update

EMA's Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh) endorsed a recommendation from the agency's Pharmacovigilance Risk Assessment Committee (PRAC) to suspend marketing authorization of oral almitrine-containing medicines in the EU. EMA said almitrine...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

Almitrine-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that all marketing authorizations for oral almitrine-containing medicines be withdrawn across the EU after concluding that their benefits no longer outweigh their risks. EMA said almitrine has been...
07:00 , May 27, 2013 |  BC Week In Review  |  Clinical News

Almitrine regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that all marketing authorizations for oral almitrine-containing medicines be withdrawn across the EU after concluding that their benefits no longer outweigh their risks. EMA said almitrine has been...
07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...